Trump plans generic drug tariffs from 2028 with two-year delay testing U.S. onshoring push

The Trump administration's plan to impose tariffs on generic drugs from 2028, with a two-year delay, is a significant development in the ongoing effort to reshore low-cost drug production to the United States. This move is part of a broader push to reduce reliance on foreign suppliers, particularly China and India, which currently dominate the global generic drug market.

The proposed tariffs will likely face significant opposition from the pharmaceutical industry, which has long relied on low-cost suppliers from abroad to produce generic drugs. Displacing established suppliers like India, which is the largest producer of generic drugs, won't be easy. The Indian pharmaceutical industry has a well-established infrastructure, and many U.S. companies have existing partnerships with Indian manufacturers. Moreover, tariffs could lead to higher costs for consumers and potentially disrupt the supply of essential medicines.

As the trade landscape continues to evolve, it's essential to watch how the pharmaceutical industry responds to the proposed tariffs and the potential impact on drug prices and availability. Additionally, the effectiveness of the onshoring push will depend on the development of new manufacturing infrastructure in the United States and the ability of U.S. companies to compete with low-cost foreign suppliers. The next critical step will be to see how Congress and the pharmaceutical industry react to the proposed tariffs and whether alternative solutions emerge to address concerns around drug pricing and supply chain security.

Originally reported by cnbc.com. Trade-News adds analysis for finance & markets readers.